Resistance to β-lactam antibiotics

  title={Resistance to $\beta$-lactam antibiotics},
  author={Keith Poole},
  journal={Cellular and Molecular Life Sciences CMLS},
  • K. Poole
  • Published 1 August 2004
  • Biology, Chemistry
  • Cellular and Molecular Life Sciences CMLS
Abstractβ-lactams have a long history in the treatment of infectious diseases, though their use has been and continues to be confounded by the development of resistance in target organisms. β-lactamases, particularly in Gram-negative pathogens, are a major determinant of this resistance, although alterations in the β-lactam targets, the penicillin-binding proteins (PBPs), are also important, especially in Gram-positive pathogens. Mechanisms for the efflux and/or exclusion of these agents also… 

Overcoming resistance to β-lactam antibiotics.

Small molecule strategies to overcome resistance to β-lactam antibiotics include the development of β- lactamase inhibitors and compounds that interfere with the ability of the bacteria to sense an antibiotic threat and activate their resistance mechanisms.

β-Lactam Resistance Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein

It is demonstrated that high-level β-lactam resistance in vitro, in vivo, and in the clinical setting is driven by the inactivation of the dacB-encoded nonessential PBP4, which behaves as a trap target for β- lactams.

β-Lactam Antibiotics

This review traces the historical development of β-lactam drug discovery, with emphasis on the most recent progress in the medicinal chemistry, biochemistry, and microbiology of the β-Lactams leading to the discovery of new generation β- lactam antibacterials effective against the Gram-negative and -positive bacterial pathogens of current medical concern.

Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

This review focuses on the further developments in the synthetic strategies using DBO as well as boronic acid derivatives that have been developed in last few years, and binding interactions of the representative inhibitors have been discussed based on the crystal structure data of inhibitor-enzyme complex.

Evolution of Broad Spectrum β-Lactam Resistance in an Engineered Metallo-β-lactamase*

Bacterial resistance was significantly increased despite marked reductions in both mRNA and protein levels relative to those of parental evMBL9, indicating that the catalytic activities of these mutant MBLs were highly increased.

Class D β-lactamases do exist in Gram-positive bacteria

It is demonstrated that efficient class D β-lactamases capable of hydrolyzing a wide array of β- lactam substrates are widely disseminated in various species of environmental Gram-positive organisms.

An Overview of Extended Spectrum Beta Lactamases and Metallo Beta Lactamases

With increasing resistance rate to the antibiotics, it’s very essential to follow the guidelines for detection, implementation of antibiotic rotation to reduce these pathogens, followed by the efficient infection control practices and strategies to avoid such outbreaks.

Importance of Position 170 in the Inhibition of GES-Type β-Lactamases by Clavulanic Acid

Insight is provided into the importance of the residue at position 170 in determining the susceptibility of GES enzymes to clavulanic acid in β-lactamases.



The impact of beta-lactamases on the development of novel antimicrobial agents.

  • K. Bush
  • Biology, Medicine
    Current opinion in investigational drugs
  • 2002
For all agents, the multiplicity of beta-lactamases in single organisms or in mixed infections poses a new set of challenges requiring agents that can respond to enzymes with varying functional characteristics.

Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

There is evidence to suggest that they are efficacious in treating patients with neutropenic fever and nosocomial infections, especially in combination with other agents, and beta-Lactam/beta-lactamase inhibitor combinations are particularly useful against mixed infections.

Altered permeability and beta-lactam resistance in a mutant of Mycobacterium smegmatis

The results suggest that decreased affinities of PBP 1 for beta-lactams, combined with the decreased permeability of the cell wall of the mutant, lead to the development of high-level acquired beta- lactam resistance.

New findings in beta-lactam and metronidazole resistant Bacteroides fragilis group.

Recombinant Expression and Characterization of the Major β-Lactamase of Mycobacterium tuberculosis

It is concluded that the major β-lactamase of M. tuberculosis is a class A β-magnifying enzyme with predominant penicillinase activity and a second, minor β- lactamases with relatively greater cephalosporinase activity is also present.

β-Lactamase Genes of the Penicillin-Susceptible Bacillus anthracis Sterne Strain

The presence of two beta-lactamase (bla) genes in the penicillin-susceptible Sterne strain of B. anthracis Sterne strains indicate that the bla1 and bla2 genes of the B. Anthracis group species harboring bla promoter-lacZ transcriptional fusions are poorly transcribed, but gene expression is usually not sufficient to confer resistance to beta- lactam agents.

Structural basis for the β lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus

Structures of the acyl-PBP complexes of PBP2a with nitrocefin, penicillin G and methicillin allow, for the first time, a comparison of an apo and acylated resistant PBP.

The resistance mechanisms of b-lactam antimicrobials in clinical isolates of Acinetobacter baumannii

In two strains with an elevated MIC of imipenem, a decrease or loss of about 35 kDa and 22 kDa proteins in OMP was observed, which suggested that the change of OMP played a role in carbapenem resistance.

PBP 2a Mutations Producing Very-High-Level Resistance to Beta-Lactams

The emergence of P BP 2a-mediated resistance to beta-lactams that bind to PBP 2a with a high affinity is likely to require multiple mutations in mecA; chromosomal mutations appear to have a minor role.